Floatz logo

Glb-001

Essential Thrombocythemia

Hangzhou GluBio Pharmaceutical Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Essential Thrombocythemia cohort.

Asset / SponsorPhaseRating
TACROLIMUS
Thomas Jefferson University
Phase 2BB
Fludarabine
Thomas Jefferson University
Phase 2BB
Ruxolitinib
University of Washington
Phase 2B
Cyclophosphamide
Thomas Jefferson University
Phase 2B
Hycamtin
National Cancer Institute (NCI)
Phase 2B

View all 31 →

Same molecule, other indications

Glb-001 is also rated in:

acquired polycythemia veraDormant
CC
Indicative ·
43 / 100
View asset →
myeloid neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
myelofibrosisDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →